is the fda taking tirzepatide off the market Eli Lilly's FDA's drug shortage list: Here's what it means FDA reconsidering its decision to

Melanotan II is a synthetic peptide shown to have many positive effects on body composition and energy homeostasis

Zhang, 2024)

Therefore, it is essential to develop an easy and convenient POCT that is applicable in various settings including local hospitals, veterinary clinics, and animal farms

Kruse, Thomas

And as such, discontinuing supplemental treatment will simply result in hormone levels steadily decreasing back to where they were originally

ChAdOx/MVA viral vectors / CancerProstate cancerPhase 1Pursuing partnership opportunities for advancementWorldwide rights 3assets LOQTORZI (toripalimab-tpzi)LOQTORZI / PD-1 / Anti-PD-1 monoclonal antibody / Oncology1L Nasopharyngeal Carcinoma (combo with chemotherapy)ApprovedApprovedUnited States2L+ Nasopharyngeal Carcinoma (monotherapy)ApprovedApprovedUnited States TagmokitugCHS-114 / CCR8 / Anti-CCR8 monoclonal antibody / Oncology4L+ Colorectal Cancer (combo with toripalimab)Phase 22L HNSCC (combo with toripalimab)Phase 12L Gastric Cancer/GEJ/EAC (combo with toripalimab)Phase 1 CasdozokitugIL-27 / IL-27 antagonist monoclonal antibody / Oncology1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)Phase 2 3assets CTx-1301CTx-1301 / PTR multi-core modified-release dexmethylphenidate tablet / CNSADHDNDA submittedSubmitted July 31, 2025US CTx-1302CTx-1302 / PTR multi-core modified-release dextroamphetamine tablet / CNSADHDPreclinical/formulationInitial formulation study plannedUS CTx-2103CTx-2103 / 5-HT1A partial agonist / PTR multi-core modified-release buspirone tablet / CNSAnxietyPre-INDClinical trials planned 4Q 2026US 3assets Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic